Position in GNLX
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$1,323,200
+$340,991 QoQ
Shares Held
439,602
+8.3% QoQ
Ownership
0.972%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#4
of 72 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BlackRock, Inc. holds $85,603,777,939 across 474 Biotechnology names. GNLX ranks #317 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
24,109,373 | $11,975,848,839 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,113,506 | $5,682,635,520 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
10,907,675 | $3,283,537,392 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
13,695,790 | $2,564,947,540 | |
| 5 | MRNA |
Moderna, Inc.
|
30,599,409 | $2,142,876,602 | |
| 6 | INCY |
Incyte Corp
|
18,032,718 | $2,044,188,902 | |
| 7 | CYTK |
Cytokinetics Inc
|
20,094,362 | $1,711,838,691 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
48,236,091 | $1,707,075,250 |
All Filings in GNLX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,323,200 | 439,602 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $982,209 | 405,872 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,679,940 | 385,308 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,595,529 | 379,888 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $932,699 | 324,983 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $944,390 | 349,775 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $817,039 | 346,204 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $735,378 | 310,287 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||